• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Top 3 Health Care Stocks That Could Blast Off In June

    6/21/24 8:22:13 AM ET
    $ENOV
    $PEN
    $RGEN
    Industrial Specialties
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $ENOV alert in real time by email

    The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

    The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro.

    Here's the latest list of major oversold players in this sector, having an RSI near or below 30.

    Repligen Corp (NASDAQ:RGEN)

    • On June 13, Repligen named Olivier Loeillot as Chief Executive Officer, effective Sept. 1. The company's stock fell around 28% over the past month and has a 52-week low of $110.45.
    • RSI Value: 22.62
    • RGEN Price Action: Shares of Repligen fell 2.4% to close at $120.00 on Thursday.
    • Benzinga Pro's real-time newsfeed alerted to latest RGEN’s news.

    Enovis Corp (NYSE:ENOV)         

    • On May 2, Enovis posted better-than-expected quarterly results. “We had a great start to 2024, with both revenues and operating margins exceeding expectations,” said Matt Trerotola, Chief Executive Officer of Enovis.” The company's stock fell around 12% over the past month. It has a 52-week low of $43.04.
    • RSI Value: 25.21
    • ENOV Price Action: Shares of Enovis fell 0.1% to close at $44.56 on Thursday.
    • Benzinga Pro's charting tool helped identify the trend in ENOV’s stock.

    Penumbra Inc (NYSE:PEN)

    • On May 7, Penumbra posted upbeat quarterly earnings. The company's stock fell around 8% over the past five days and has a 52-week low of $170.59.
    • RSI Value: 28.39
    • PEN Price Action: Shares of Penumbra fell 0.3% to close at $175.45 on Thursday.
    • Benzinga Pro's signals feature notified of a potential breakout in PEN’s shares.

    Read More: Over $28M Bet On This Energy Stock? Check Out These 3 Stocks Insiders Are Buying

    Get the next $ENOV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ENOV
    $PEN
    $RGEN

    CompanyDatePrice TargetRatingAnalyst
    Enovis Corporation
    $ENOV
    1/6/2026$41.00Buy
    BTIG Research
    Penumbra Inc.
    $PEN
    12/18/2025$370.00Neutral → Overweight
    Analyst
    Penumbra Inc.
    $PEN
    12/11/2025$350.00Neutral → Buy
    Citigroup
    Penumbra Inc.
    $PEN
    11/18/2025$15.00Underweight
    Wells Fargo
    Penumbra Inc.
    $PEN
    10/8/2025$326.00Hold → Buy
    Needham
    Repligen Corporation
    $RGEN
    10/1/2025$150.00Buy
    HSBC Securities
    Repligen Corporation
    $RGEN
    9/22/2025$155.00In-line → Outperform
    Evercore ISI
    Penumbra Inc.
    $PEN
    9/2/2025$300.00Outperform
    Evercore ISI
    More analyst ratings

    $ENOV
    $PEN
    $RGEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research initiated coverage on Enovis Corporation with a new price target

    BTIG Research initiated coverage of Enovis Corporation with a rating of Buy and set a new price target of $41.00

    1/6/26 8:55:57 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    Penumbra upgraded by Analyst with a new price target

    Analyst upgraded Penumbra from Neutral to Overweight and set a new price target of $370.00

    12/18/25 8:43:06 AM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    Penumbra upgraded by Citigroup with a new price target

    Citigroup upgraded Penumbra from Neutral to Buy and set a new price target of $350.00

    12/11/25 8:45:41 AM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    $ENOV
    $PEN
    $RGEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Grewal Harpreet was granted 589 shares, increasing direct ownership by 7% to 8,819 units (SEC Form 4)

    4 - Penumbra Inc (0001321732) (Issuer)

    2/18/26 8:05:02 PM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    Director Bose Arani was granted 589 shares, increasing direct ownership by 106% to 1,147 units (SEC Form 4)

    4 - Penumbra Inc (0001321732) (Issuer)

    2/18/26 8:04:57 PM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    Director Leeds Janet was granted 589 shares, increasing direct ownership by 10% to 6,639 units (SEC Form 4)

    4 - Penumbra Inc (0001321732) (Issuer)

    2/18/26 8:04:31 PM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    $ENOV
    $PEN
    $RGEN
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Repligen Corporation

    SCHEDULE 13G/A - REPLIGEN CORP (0000730272) (Subject)

    2/17/26 10:26:21 AM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Penumbra Inc.

    SCHEDULE 13G/A - Penumbra Inc (0001321732) (Subject)

    2/6/26 1:11:50 PM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    SEC Form SCHEDULE 13G filed by Repligen Corporation

    SCHEDULE 13G - REPLIGEN CORP (0000730272) (Subject)

    2/5/26 1:36:41 PM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ENOV
    $PEN
    $RGEN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Principal Accounting Officer Kleckner John bought $74,830 worth of shares (2,468 units at $30.32), increasing direct ownership by 25% to 12,302 units (SEC Form 4)

    4 - Enovis CORP (0001420800) (Issuer)

    11/28/25 4:30:09 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    Chief Executive Officer Mcdonald Damien bought $199,973 worth of shares (6,457 units at $30.97), increasing direct ownership by 7% to 102,753 units (SEC Form 4)

    4 - Enovis CORP (0001420800) (Issuer)

    9/11/25 5:59:16 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    SVP and Chief Legal Officer Tandy Bradley J bought $100,512 worth of shares (3,200 units at $31.41), increasing direct ownership by 8% to 43,515 units (SEC Form 4)

    4 - Enovis CORP (0001420800) (Issuer)

    8/25/25 6:30:04 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    $ENOV
    $PEN
    $RGEN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Repligen to Report Fourth Quarter and Full Year 2025 Financial Results

    WALTHAM, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter 2025 financial results on Tuesday, February 24, 2026. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- and twelve- month reporting periods ended December 31, 2025. The conference call will be accessible by dialing toll-free (800) 715-9871 for domestic callers and (646) 307-1963 for international callers. No passcode is required for the live call. In addition, a webcast will be accessible via the Investor Relations sec

    2/10/26 7:30:00 AM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Boston Scientific announces results for fourth quarter and full year 2025

    MARLBOROUGH, Mass., Feb. 4, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) generated net sales of $5.286 billion during the fourth quarter of 2025, growing 15.9 percent on a reported basis, 14.3 percent on an operational1 basis and 12.7 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $672 million or $0.45 per share (EPS), compared to $566 million or $0.38 per share a year ago, and achieved adjusted3 EPS of $0.80 for the period, compared to $0.70 a year ago.

    2/4/26 6:30:00 AM ET
    $BSX
    $PEN
    Medical/Dental Instruments
    Health Care

    Enovis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

    Dallas TX, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven, medical technology growth company, today announced that management will participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Wednesday, February 11, 2026 in Snowbird, UT. About Enovis Enovis™ (NYSE:ENOV) is a global medical technology innovator dedicated to improving lives by developing clinically differentiated solutions that enhance patient outcomes and restore motion for life. We partner with the brightest minds in health to advance care that is smarter, personalized, and more effective, while improving operational efficiency for su

    2/3/26 8:00:00 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    $ENOV
    $PEN
    $RGEN
    Leadership Updates

    Live Leadership Updates

    View All

    Enovis Appoints Oliver Engert as Chief Administrative Officer

    Dallas, TX, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven medical technology company, has announced that Oliver Engert has been appointed Chief Administrative Officer, effective today. In this newly-created role, Oliver will be responsible for leading Enovis' strategy development, driving organizational efficiency and enhancing operational excellence to support the company in its next phase of profitable, capital-efficient growth. Damien McDonald, CEO of Enovis said, "Oliver's appointment comes at a very exciting time for Enovis. As we take steps to build on our strong foundation and unlock our future potential, his extensive knowledge, skills a

    1/5/26 4:15:00 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    New Survey Shows Management of Blood Clots is Inconsistent, Even for Patients with the Same Risk Profile

    Survey Conducted by the Get Out the Clot Campaign, an Initiative Focused on Identifying and Closing Gaps in Patient Care for Blood Clots ALAMEDA, Calif., Sept. 9, 2025 /PRNewswire/ -- The American Venous Forum (AVF), International Society on Thrombosis and Haemostasis (ISTH), National Blood Clot Alliance (NBCA), Penumbra (NYSE:PEN), The PERT Consortium® and Society for Vascular Medicine (SVM), which have come together to form the Get Out the Clot campaign, today announced findings from a new survey assessing the current state of venous thromboembolism (VTE) care, also known as blood clots in the body. Get Out the Clot is a collaborative educational initiative to help identify gaps in patient

    9/9/25 9:00:00 AM ET
    $PEN
    Medical/Dental Instruments
    Health Care

    908 Devices Appoints Christopher D. Brown to its Board of Directors

    908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that it has appointed Christopher D. Brown, PhD, Vice President, Analytics R&D at Repligen Corporation (NASDAQ:RGEN), and a 908 Devices Co-founder, to serve on its Board of Directors, effective immediately. Dr. Brown co-founded 908 Devices and served as the company's Chief Technology Officer & Vice President of Research & Development from February 2012 to March 2023, and as its Chief Product Officer from March 2023 until March 2025 when Repligen purchased the company's bioprocessing portfolio. Prior to 908 Devices, Dr. Brown was a platform architect at Apple Inc. (NASDAQ:AAPL) lead

    6/16/25 8:00:00 AM ET
    $AAPL
    $MASS
    $RGEN
    Computer Manufacturing
    Technology
    Industrial Machinery/Components
    Industrials

    $ENOV
    $PEN
    $RGEN
    Financials

    Live finance-specific insights

    View All

    Repligen to Report Fourth Quarter and Full Year 2025 Financial Results

    WALTHAM, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter 2025 financial results on Tuesday, February 24, 2026. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- and twelve- month reporting periods ended December 31, 2025. The conference call will be accessible by dialing toll-free (800) 715-9871 for domestic callers and (646) 307-1963 for international callers. No passcode is required for the live call. In addition, a webcast will be accessible via the Investor Relations sec

    2/10/26 7:30:00 AM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Boston Scientific announces results for fourth quarter and full year 2025

    MARLBOROUGH, Mass., Feb. 4, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) generated net sales of $5.286 billion during the fourth quarter of 2025, growing 15.9 percent on a reported basis, 14.3 percent on an operational1 basis and 12.7 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $672 million or $0.45 per share (EPS), compared to $566 million or $0.38 per share a year ago, and achieved adjusted3 EPS of $0.80 for the period, compared to $0.70 a year ago.

    2/4/26 6:30:00 AM ET
    $BSX
    $PEN
    Medical/Dental Instruments
    Health Care

    Enovis to Host Fourth Quarter and Full Year 2025 Results Conference Call on February 26th

    Dallas, TX, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its fourth quarter and full year 2025 financial results on Thursday, February 26th, 2026 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. The live webcast and a presentation related to the call will be accessible from the "Investors" section of Enovis' website at www.enovis.com. Conference Call/Webcast Information Investors can access the live webcast via a link on the Enovis website. For those planning to participate on the call, pleas

    1/23/26 8:30:00 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    $ENOV
    $PEN
    $RGEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Enovis Corporation

    SC 13G/A - Enovis CORP (0001420800) (Subject)

    11/14/24 1:28:31 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    Amendment: SEC Form SC 13G/A filed by Repligen Corporation

    SC 13G/A - REPLIGEN CORP (0000730272) (Subject)

    11/14/24 1:22:37 PM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Penumbra Inc.

    SC 13G/A - Penumbra Inc (0001321732) (Subject)

    11/14/24 1:22:36 PM ET
    $PEN
    Medical/Dental Instruments
    Health Care